Premium
OESTROGEN RECEPTOR ASSAY IN PRIMARY BREAST CANCER: CLINICAL VALIDATION AND PROGNOSTIC VALUE
Author(s) -
FURNIVAL C. M.,
HlLLYARD N. C.,
GOUGH I. R.
Publication year - 1982
Publication title -
australian and new zealand journal of surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.111
H-Index - 51
eISSN - 1445-2197
pISSN - 0004-8682
DOI - 10.1111/j.1445-2197.1982.tb06019.x
Subject(s) - medicine , oestrogen receptor , breast cancer , oncology , cancer , hormone receptor , receptor , disease , gynecology , cancer research , pathology
The results of a cytoplasmic oestrogen receptor assay in 134 cases of primary breast cancer are reported. Overall, 57% of primary cancers tested were oestrogen‐receptor ‘positive’ (ER +) and attention is drawn to the need for careful initial handling of tumour tissue, to ensure an accurate assay result. ER+ tumours occurred more often and showed higher assay values in postmenopausal compared with premenopausal women and nine of 12 ER+ tumours responded to hormone manipulation when disease recurred. Follow‐up of primary disease confirmed that women with ER+ tumours have a better prognosis with a lower risk of early recurrence than those with ER‐ tumours. It is suggested that clinical validation of the oestrogen receptor assay should precede routine clinical use.